CoronaryAtlas logo
CoronaryAtlas
Lipoprotein lipase
Pathway / Lipid retention & oxidation

Lipoprotein lipase

LPLprotein

Rate-limiting enzyme hydrolyzing triglycerides in atherogenic lipoproteins, regulated by ANGPTL inhibitors.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleTriglyceride hydrolysis, regulated lipoprotein metabolism controlling atherogenic substrate.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000175445

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
66
C — confounder / Type-II
81
A — assay feasibility
68
E — evidence strength
31
T1DI (composite)
9
Specificity differential (R−C)-14.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.581
Open Targets association (myocardial_infarction)
5
GWAS associations
Traits: myocardial infarction

Literature evidence(8)